Next GEN Act of 2026

This bill amends the Social Security Act to change how certain engineered cyclic peptides are treated under the Drug Price Negotiation Program. It extends the period before these drugs become eligible for price negotiation from 7 years to 11 years and defines what qualifies as an engineered cyclic peptide.

Sec. 2, Adjusting rules for engineered cyclic peptides under Drug Price Negotiation Program: The bill modifies the definition of a qualifying single source drug to give engineered cyclic peptides an 11-year period before they are subject to price negotiation, instead of the standard 7 years. It also adds a new definition for engineered cyclic peptides, which are polymers made mostly of amino acids, have at least one cyclic structure, contain no more than 40 amino acids, were identified using a genetically encoded library screening method, are not naturally derived, and are administered orally, inhaled, or self-administered. These changes apply to drug lists published on or after the bill's enactment date.